Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule 16b-3

NRIX Stock  USD 21.82  0.23  1.04%   
Slightly above 66% of Nurix Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Nurix Therapeutics suggests that many traders are alarmed. Nurix Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Nurix Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Nurix Therapeutics Officer: Chief Legal Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at investing.com
Investing News at Macroaxis
  
Disposition of 3290 common stock at 25.0 of Nurix Therapeutics by Christine Ring on 4th of November 2024. This event was filed by Nurix Therapeutics with SEC on 2024-11-04. Statement of changes in beneficial ownership - SEC Form 4

Nurix Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Nurix Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Nurix Therapeutics Fundamental Analysis

We analyze Nurix Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Nurix Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Nurix Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nurix Therapeutics stock to make a market-neutral strategy. Peer analysis of Nurix Therapeutics could also be used in its relative valuation, which is a method of valuing Nurix Therapeutics by comparing valuation metrics with similar companies.

Peers

Nurix Therapeutics Related Equities

NKTXNkarta   5.71   
0%
100.0%
KYMRKymera Therapeutics   4.54   
0%
79.0%
PLRXPliant Therapeutics   3.70   
0%
64.0%
CCCCC4 Therapeutics   3.06   
0%
53.0%
STOKStoke Therapeutics   3.06   
0%
53.0%
RLAYRelay Therapeutics   2.32   
0%
40.0%
GBIOGeneration Bio   2.19   
0%
38.0%
PRLDPrelude Therapeutics   1.05   
0%
18.0%
STTKShattuck Labs   1.00   
0%
17.0%
FHTXFoghorn Therapeutics   0.77   
0%
13.0%
GLUEMonte Rosa   0.35   
6.0%
0%
BDTXBlack Diamond   1.18   
20.0%
0%
ELYMEliem Therapeutics   2.60   
45.0%
0%
ARVNArvinas   2.75   
48.0%
0%
LYELLyell Immunopharma   4.21   
73.0%
0%
SANASana Biotechnology   4.98   
87.0%
0%

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.